Details for Patent: 11,179,367
✉ Email this page to a colleague
Which drugs does patent 11,179,367 protect, and when does it expire?
Patent 11,179,367 protects TRIKAFTA (COPACKAGED) and is included in two NDAs.
This patent has fifteen patent family members in thirteen countries.
Summary for Patent: 11,179,367
| Title: | Pharmaceutical compositions for treating cystic fibrosis |
| Abstract: | A pharmaceutical composition comprising Compound I: ##STR00001## Methods of treating cystic fibrosis comprising administering one or more of such pharmaceutical compositions to a patient. |
| Inventor(s): | Chu; Cathy (Cambridge, MA), Dhamankar; Varsha (Watertown, MA), Dokou; Eleni (Cambridge, MA), Haseltine; Eric L. (Melrose, MA), Moskowitz; Samuel (Waban, MA), Robertson; Sarah (Somerville, MA), Waltz; David (Waban, MA), Chen; Weichao George (San Diego, CA) |
| Assignee: | Vertex Pharmaceuticals Incorporated (Boston, MA) |
| Application Number: | 16/267,222 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Compound; Dosage form; |
Drugs Protected by US Patent 11,179,367
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vertex Pharms Inc | TRIKAFTA (COPACKAGED) | elexacaftor, ivacaftor, tezacaftor; ivacaftor | GRANULES;ORAL | 217660-001 | Apr 26, 2023 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 2 TO | ⤷ Sign Up | |||
| Vertex Pharms Inc | TRIKAFTA (COPACKAGED) | elexacaftor, ivacaftor, tezacaftor; ivacaftor | GRANULES;ORAL | 217660-002 | Apr 26, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 2 TO | ⤷ Sign Up | |||
| Vertex Pharms Inc | TRIKAFTA (COPACKAGED) | elexacaftor, ivacaftor, tezacaftor; ivacaftor | TABLET;ORAL | 212273-002 | Jun 8, 2021 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A MUTATION THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH A COMPOSITION ACCORDING TO AT LEAST ONE OF CLAIMS 1-9 OF US11179367 | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,179,367
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 114581 | ⤷ Sign Up | |||
| Australia | 2019215231 | ⤷ Sign Up | |||
| Brazil | 112020014487 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
